Neuromodulation Market – [Spinal Cord Stimulation (SCS), Vagus Nerve Stimulation (VNS), Gastric Electrical Stimulation (GES), Deep Brain Stimulation (DBS), Sacral Nerve Stimulation (SNS), & Transcranial Magnetic Stimulation (TMS)] – Forecasts to 2017

• Publication date: January 2013
• Report size: 193 pages

Neuromodulation devices have emerged as one of the fastest growing segments of the medical device market due to high demand for minimally invasive and non–invasive treatment. With advancements in technology, neuromodulation is expected to become a promising therapeutic area and high growth industry in the next decade, as it offers symptomatic relief mainly from chronic pain, incontinence, heart failure, headache, depression, epilepsy, etc. The ...

Neuromodulation devices have emerged as one of the fastest growing segments of the medical device market due to high demand for minimally invasive and non–invasive treatment. With advancements in technology, neuromodulation is expected to become a promising therapeutic area and high growth industry in the next decade, as it offers symptomatic relief mainly from chronic pain, incontinence, heart failure, headache, depression, epilepsy, etc. The neuromodulation devices market includes deep brain stimulation, spinal cord stimulation, vagus nerve stimulation, sacral nerve stimulation and others external stimulation devices such as transcranial magnetic stimulation, and transcutaneous electrical nerve stimulation (TENS).

The neuromodulation technique acts directly upon nerves or the target area where the activity of nerves is altered due to biological responses produced by electrical stimulation or drug infusion. These devices include small electrodes that are attached to the brain, the spinal cord, or peripheral nerves. These precisely placed leads are connected by means of an extension cable to a pulse generator to generate electrical stimulation. Neuromodulation can have applications in any area of the body and can treat several diseases like chronic pain, epilepsy, psychiatric disorder, movement disorder, cardiovascular disorder, genitourinary and colorectal disorder, stroke and brain injury, and gastric disorder.

The main drivers for the neuromodulation market are the rising population of aged people and age-related diseases like Alzheimer’s, epilepsy, spinal cord injury, and Parkinson’s disease. According to the International Neuromodulation Society, about 40 million to 50 million patients worldwide suffer from epilepsy, and 1.5 million people currently (2012) suffer from Parkinson disease in the U.S. The large pool of patients that suffer from depression, stroke, anxiety disorders, lower back pain, urinary incontinence, and tremor offers the neuromodulation industry opportunities to grow in the next five years. The market for treatment of tinnitus, in particular, represents an emerging application of neuromodulation. According to the American Tinnitus Association, about 50 million people currently (2012) suffer from this disease in the U.S.

This report estimates the market for six major segments, namely, spinal cord stimulation, deep brain stimulation, sacral nerve stimulation, vagus nerve stimulation, gastric electrical stimulation, transcranial magnetic stimulation, and others. The report also estimates the market for different neuromodulation techniques as well as geographic analysis of each segment in North America, Europe, Asia-Pacific, and Rest of the World. As technologies develop and the number of trained physician increases, the likelihood of neuromodulation being seen as life-changing treatment will increase dramatically. It is estimated that the market for neuromodulation will be shared largely by deep brain stimulation and spinal cord stimulation.

The key players in the neuromodulation devices market are Medtronic, Inc. (U.S.), Cyberonics, Inc. (U.S.), Boston Scientific Corporation (U.S.), St. Jude Medical (U.S.), Enteromedics, Inc (U.S.), Neuropace, Inc (U.S.), Zynex, Inc (U.S.) and Neuronetics, Inc (U.S.). The emerging players in this market are Functional Neuromodulation, Ltd (U.S.), Microtransponder (U.S.), and Neurosigma, Inc (U.S.).

Scope of the Report

The research report categorizes the global neuromodulation devices market by procedure, technology, and application. These markets are broken down into segments and sub-segments, providing exhaustive value-volume analysis for 2010, 2011, and 2012 as well as forecast up to 2017. Each market is also analyzed by geography (North America, Europe, Asia-Pacific, and Rest of the World to provide in-depth information on the global scenario.

Global Neurostimulation Devices Market, by Procedure:

Internal Neurostimulation
Spinal Cord Stimulation (SCS)
Failed Back Surgery Syndrome
Chronic Pain
Ischemic Pain
Others
Deep Brain Stimulation (DBS)
Movement Disorders
Parkinson’s Disease
Alzheimer’s Disease
Dystonia
Tourette’s Syndrome
Others
Chronic Pain
Depression
Post-Traumatic Coma
Sacral Nerve Stimulation (SNS)
Urine Incontinence
Fecal Incontinence
Vagus Nerve Stimulation (VNS)
Epilepsy disease
Heart Failure
Tinnitus
Others
Gastric Electrical Stimulation (GES)
Gastroparesis
Others
External Neurostimulation
Transcranial Magnetic Stimulation (TMS)
Depression
Tinnitus
Migraine
Stroke
Others
Transcutaneous Electrical Nerve Stimulation (TENS)
Global Neurostimulation Devices Market, by Geography

North America
Europe
Asia-Pacific
Rest of the World

Pathology Industry in Europe

TABLE OF CONTENTS

1 INTRODUCTION 16
1.1 KEY TAKE-AWAYS 16
1.2 REPORT DESCRIPTION 16
1.3 MARKETS COVERED 18
1.4 RESEARCH METHODOLOGY 20
1.4.1 MARKET SIZE 20
1.4.2 MARKET SHARE 20
1.4.3 KEY DATA POINTS FROM SECONDARY SOURCES 20
1.4.4 KEY DATA POINTS FROM PRIMARY SOURCES 21
1.4.5 ASSUMPTIONS 21
1.5 STAKEHOLDERS 21
2 EXECUTIVE SUMMARY 22
3 MARKET OVERVIEW 25
3.1 INTRODUCTION 26
3.2 MARKET SEGMENTATION 27
3.3 MARKET DYNAMICS 29
3.3.1 DRIVERS 29
3.3.1.1 Increasing incidence of neurological disorders to spur market growth 29
3.3.1.2 Unprecedented global aging to fuel market growth 29
3.3.1.3 Strong product pipeline to propel the market 30
3.3.1.4 Expanded target applications and new indications are expected to stimulate growth of neuromodulation devices 30
3.3.1.5 Investments and funds – an impetus for market growth 31
3.4 RESTRAINTS 32
3.4.1.1 An unfavourable reimbursement scenario hinders market growth 32
3.4.1.2 Lack of trained professionals likely to hamper market growth 33
3.5 MARKET SHARE ANALYSIS 33
4 GLOBAL NEUROMODULATION MARKET (INTERNAL & EXTERNAL) 35
4.1 INTRODUCTION 36
4.2 INTERNAL STIMULATION 37
4.2.1 SPINAL CORD STIMULATION (SCS) MARKET 37
4.2.1.1 Major applications 39
4.2.1.1.1 Failed back surgery syndrome 40
4.2.1.1.2 Chronic pain 40
4.2.1.1.3 Ischemia 42
4.2.2 DEEP BRAIN STIMULATION (DBS) 42
4.2.2.1 Major applications 45
4.2.2.1.1 Parkinson’s disease 46
4.2.2.1.2 Dystonia 47
4.2.2.1.3 Tremor 47
4.2.2.1.4 Alzheimer’s 48
4.2.3 SACRAL NERVE STIMULATION (SNS) 48
4.2.3.1 Major applications 51
4.2.3.1.1 Urine incontinence 52
4.2.3.1.2 Fecal incontinence 53
4.2.4 VAGUS NERVE STIMULATION (VNS) 53
4.2.4.1 Major applications 56
4.2.4.1.1 Epilepsy 57
4.2.4.1.2 Others 58
4.2.5 GASTRIC ELECTRICAL STIMULATION (GES) 58
4.3 EXTERNAL STIMULATION 61
4.3.1 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) 61
4.3.2 TRANSCRANIAL MAGNETIC STIMULATION (TMS) 64

5 GEOGRAPHIC ANALYSIS 68
5.1 INTRODUCTION 69
5.2 NORTH AMERICA 72
5.3 EUROPE 80
5.4 ASIA 87
5.5 REST OF THE WORLD 97
6 COMPETITIVE LANDSCAPE 106
6.1 INTRODUCTION 106
6.2 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS, CONTRACTS & JOINT VENTURES 108
6.3 NEW PRODUCT LAUNCH 110
6.4 EXPANSION 112
6.5 OTHER DEVELOPMENTS 113
6.6 APPROVALS 114
7 COMPANY PROFILES 122
(Overview, Financials, Products & Services, Strategy, & Developments)*
7.1 ANM ADAPTIVE NEUROMODULATION GMBH 122
7.2 BIOCONTROL MEDICAL, LTD. 125
7.3 BOSTON SCIENTIFIC CORPORATION 128
7.4 CERBOMED GMBH 136
7.5 CYBERONICS, INC. 139
7.6 ENDOSTIM, INC. 144
7.7 ENTEROMEDICS, INC. 147
7.8 THE MAGSTIM COMPANY LIMITED 150
7.9 MEDTRONIC, INC. 153
7.10 NEURONETICS, INC. 159
7.11 NEUROPACE, INC. 162
7.12 NEUROSIGMA, INC. 164
7.13 NEVRO CORPORATION 167
7.14 RS MEDICAL 169
7.15 SPINAL MODULATION, INC. 172
7.16 ST. JUDE MEDICAL 174
7.17 SYNAPSE BIOMEDICAL, INC. 182
7.18 UROPLASTY, INC. 184
7.19 ZYNEX, INC. 188
*Details on financials, product & services, strategy, and developments might not be captured in case of unlisted companies.


LIST OF TABLES


TABLE 1 GLOBAL NEUROMODULATION MARKET, BY PROCEDURE,
2010 – 2017 ($MILLION) 23
TABLE 2 GLOBAL NEUROMODULATION MARKET, BY MODALITY,
2010 – 2017 ($MILLION) 23
TABLE 3 SPINAL CORD STIMULATION MARKET, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 38
TABLE 4 SPINAL CORD STIMULATION MARKET VOLUME, BY GEOGRAPHY,
2010 – 2017 (NO OF UNITS) 39
TABLE 5 GLOBAL SPINAL CORD STIMULATION MARKET, BY APPLICATION,
2010 – 2017 ($MILLION) 41
TABLE 6 DEEP BRAIN STIMULATION MARKET, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 44
TABLE 7 DEEP BRAIN STIMULATION MARKET VOLUME, BY GEOGRAPHY,
2010-2017 (NO OF UNITS) 45
TABLE 8 GLOBAL DEEP BRAIN STIMULATION MARKET, BY APPLICATION,
2010 – 2017 ($MILLION) 46
TABLE 9 SACRAL NERVE STIMULATION MARKET, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 50
TABLE 10 SACRAL NERVE STIMULATION MARKET VOLUME, BY GEOGRAPHY,
2010 – 2017 (NO OF UNITS) 51
TABLE 11 GLOBAL SACRAL NERVE STIMULATION MARKET, BY APPLICATION,
2010 – 2017 ($MILLION) 52
TABLE 12 VAGUS NERVE STIMULATION MARKET, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 55
TABLE 13 VAGUS NERVE STIMULATION MARKET VOLUME, BY GEOGRAPHY,
2010 – 2017 (NO OF UNITS) 56
TABLE 14 GLOBAL VAGUS NERVE STIMULATION MARKET, BY APPLICATION,
2010 – 2017 ($MILLION) 57
TABLE 15 GASTRIC ELECTRICAL STIMULATION MARKET, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 59
TABLE 16 GASTRIC ELECTRICAL STIMULATION MARKET VOLUME,
BY GEOGRAPHY, 2010 – 2017 (NO OF UNITS) 60
TABLE 17 GLOBAL GASTRIC ELECTRICAL STIMULATION MARKET,
BY APPLICATION, 2010-2017 ($MILLION) 61
TABLE 18 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET,
BY GEOGRAPHY, 2010 – 2017($MILLION) 63
TABLE 19 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET VOLUME, BY GEOGRAPHY, 2010 – 2017 (NO OF UNITS) 64
TABLE 20 TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 65
TABLE 21 TRANSCRANIAL MAGNETIC STIMULATION MARKET VOLUME,
BY GEOGRAPHY, 2010 – 2017 (NO OF UNITS) 66
TABLE 22 GLOBAL TRANSCRANIAL MAGNETIC STIMULATION MARKET,
BY APPLICATION, 2010 – 2017 ($MILLION) 67
TABLE 23 NEUROMODULATION DEVICES MARKET, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 69
TABLE 24 EXTERNAL NEUROMODULATION DEVICES MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 70
TABLE 25 INTERNAL NEUROMODULATION DEVICES MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 71
TABLE 26 GLOBAL EXTERNAL NEUROMODULATION MARKET, BY MODALITY,
2010 – 2017 ($MILLION) 71
TABLE 27 GLOBAL EXTERNAL NEUROMODULATION DEVICES MARKET VOLUME,
BY MODALITY, 2010 – 2017 (NO OF UNITS) 72
TABLE 28 NORTH AMERICA: NEUROMODULATION DEVICES MARKET,
BY PROCEDURE, 2010 – 2017 ($MILLION) 73
TABLE 29 NORTH AMERICA: INTERNAL NEUROMODULATION DEVICES MARKET, BY MODALITY, 2010 – 2017 ($MILLION) 74
TABLE 30 NORTH AMERICA: INTERNAL NEUROMODULATION DEVICES MARKET VOLUME, BY MODALITY, 2010 – 2017 (NO. OF UNITS) 75
TABLE 31 NORTH AMERICA: EXTERNAL NEUROMODULATION DEVICES MARKET, BY MODALITY, 2010 – 2017 ($MILLION) 75
TABLE 32 NORTH AMERICA: EXTERNAL NEUROMODULATION DEVICES MARKET VOLUME, BY MODALITY, 2010 – 2017 (NO. OF UNITS) 76
TABLE 33 NORTH AMERICA: SPINAL CORD STIMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 76
TABLE 34 NORTH AMERICA: DEEP BRAIN STIMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 77
TABLE 35 NORTH AMERICA: SACRAL NERVE STIMULATION, BY COUNTRY,
2010 – 2017 ($MILLION) 77
TABLE 36 NORTH AMERICA: VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 78
TABLE 37 NORTH AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET,
BY COUNTRY, 2010 – 2017 ($MILLION) 78
TABLE 38 NORTH AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 79
TABLE 39 NORTH AMERICA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 79
TABLE 40 EUROPE: NEUROMODULATION DEVICES MARKET, BY PROCEDURE,
2010 – 2017 ($MILLION) 81
TABLE 41 EUROPE: INTERNAL NEUROMODULATION DEVICES MARKET,
BY MODALITY, 2010 – 2017 ($MILLION) 81
TABLE 42 EUROPE: INTERNAL NEUROMODULATION DEVICES MARKET VOLUME, BY MODALITY, 2010 – 2017 (NO. OF UNITS) 82
TABLE 43 EUROPE: EXTERNAL NEUROMODULATION DEVICES MARKET,
BY MODALITY, 2010 – 2017 ($MILLION) 83
TABLE 44 EUROPE: EXTERNAL NEUROMODULATION DEVICES MARKET VOLUME, BY MODALITY, 2010 – 2017 (NO. OF UNITS) 83
TABLE 45 EUROPE: SPINAL CORD STIMULATION MARKET, BY REGION,
2010 – 2017 ($MILLION) 84
TABLE 46 EUROPE: DEEP BRAIN STIMULATION MARKET, BY REGION,
2010 – 2017 ($MILLION) 84
TABLE 47 EUROPE: SACRAL NERVE STIMULATION, BY REGION,
2010 – 2017 ($MILLION) 85
TABLE 48 EUROPE: VAGUS NERVE STIMULATION MARKET, BY REGION,
2010 – 2017 ($MILLION) 85
TABLE 49 EUROPE: GASTRIC ELECTRICAL STIMULATION MARKET, BY REGION, 2010 – 2017 ($MILLION) 86
TABLE 50 EUROPE: TRANSCRANIAL MAGNETIC STIMULATION MARKET,
BY REGION, 2010 – 2017 ($MILLION) 86
TABLE 51 EUROPE: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY REGION, 2010 – 2017 ($MILLION) 87
TABLE 52 ASIA: NEUROMODULATION DEVICES MARKET, BY PROCEDURE,
2010 – 2017 ($MILLION) 88
TABLE 53 ASIA: INTERNAL NEUROMODULATION DEVICES MARKET, BY MODALITY, 2010 – 2017 ($MILLION) 89
TABLE 54 ASIA: INTERNAL NEUROMODULATION DEVICES MARKET VOLUME,
BY MODALITY, 2010 – 2017 (NO. OF UNITS) 90
TABLE 55 ASIA: EXTERNAL NEUROMODULATION DEVICES MARKET,
BY MODALITY, 2010 – 2017 ($MILLION) 90
TABLE 56 ASIA: EXTERNAL NEUROMODULATION DEVICES MARKET VOLUME,
BY MODALITY, 2010 – 2017 (NO. OF UNITS) 91
TABLE 57 ASIA: SPINAL CORD STIMULATION MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 92
TABLE 58 ASIA: DEEP BRAIN STIMULATION MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 93
TABLE 59 ASIA: SACRAL NERVE STIMULATION, BY COUNTRY,
2010 – 2017 ($MILLION) 94
TABLE 60 ASIA: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 95
TABLE 61 ASIA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 96
TABLE 62 ROW: NEUROMODULATION DEVICES MARKET, BY PROCEDURE,
2010 – 2017 ($MILLION) 97
TABLE 63 ROW: INTERNAL NEUROMODULATION DEVICES MARKET, BY MODALITY, 2010 – 2017 ($MILLION) 98
TABLE 64 ROW: INTERNAL NEUROMODULATION DEVICES MARKET VOLUME,
BY MODALITY, 2010 – 2017 (NO. OF UNITS) 99
TABLE 65 ROW: EXTERNAL NEUROMODULATION DEVICES MARKET,
BY MODALITY, 2010 – 2017 ($MILLION) 99
TABLE 66 ROW: EXTERNAL NEUROMODULATION DEVICES MARKET VOLUME,
BY MODALITY, 2010 – 2017 (NO. OF UNITS) 100
TABLE 67 ROW: SPINAL CORD STIMULATION MARKET, BY REGION,
2010 – 2017 ($MILLION) 100
TABLE 68 ROW: DEEP BRAIN STIMULATION MARKET, BY REGION,
2010 – 2017 ($MILLION) 101
TABLE 69 ROW: SACRAL NERVE STIMULATION, BY REGION,
2010 – 2017 ($MILLION) 102
TABLE 70 ROW: VAGUS NERVE STIMULATION MARKET, BY REGION,
2010 – 2017 ($MILLION) 102
TABLE 71 ROW: GASTRIC ELECTRICAL STIMULATION MARKET, BY REGION,
2010 – 2017 ($MILLION) 103
TABLE 72 ROW: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY REGION, 2010 – 2017 ($MILLION) 104
TABLE 73 ROW: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY REGION, 2010 – 2017 ($MILLION) 104
TABLE 74 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS, CONTRACTS & JOINT VENTURES, 2010 – 2012 108
TABLE 75 NEW PRODUCT LAUNCH, 2010 – 2012 110
TABLE 76 EXPANSION, 2010 – 2012 112
TABLE 77 OTHER DEVELOPMENTS, 2010 – 2012 113
TABLE 78 APPROVALS, 2010 – 2012 114
TABLE 79 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION) 129
TABLE 80 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION) 129
TABLE 81 BOSTON SCIENTIFIC: TOTAL REVENUE, BY GEOGRAPHY,
2009 – 2011 ($MILLION) 130
TABLE 82 CYBERONICS, INC.: TOTAL REVENUE AND R&D EXPENDITURE,
2009 – 2011 ($MILLION) 140
TABLE 83 CYBERONICS, INC.: TOTAL REVENUE, BY GEOGRAPHY,
2009 – 2011 ($MILLION) 140
TABLE 84 MEDTRONIC, INC.: TOTAL REVENUE AND R&D EXPENDITURE,
2009 – 2011 ($MILLION) 154
TABLE 85 MEDTRONIC, INC: TOTAL REVENUE, BY SEGMENTS,
2009 – 2011 ($MILLION) 154
TABLE 86 MEDTRONIC, INC.: TOTAL REVENUE, BY GEOGRAPHY,
2009 – 2011 ($MILLION) 155
TABLE 87 ST. JUDE MEDICAL, INC: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION) 175
TABLE 88 ST. JUDE MEDICAL, INC: TOTAL REVENUE, BY SEGMENTS,
2009 – 2011 ($MILLION) 175
TABLE 89 ST. JUDE MEDICAL, INC: TOTAL REVENUE, BY GEOGRAPHY,
2009 – 2011 ($MILLION) 176
TABLE 90 UROPLASTY, INC.: TOTAL REVENUE AND R&D EXPENDITURE,
2010-2012 ($MILLION) 185
TABLE 91 UROPLASTY, INC.: TOTAL REVENUE, BY GEOGRAPHY,
2010 – 2012 ($MILLION) 185
TABLE 92 ZYNEX, INC.: TOTAL REVENUE AND R&D EXPENDITURE,
2009 – 2011 ($MILLION) 189
TABLE 93 ZYNEX, INC.: TOTAL REVENUE, BY SEGMENTS,
2009 – 2011 ($MILLION) 189

LIST OF FIGURES

FIGURE 1 NEUROMODULATION MARKET SEGMENTATION 28
FIGURE 2 MARKET DYNAMICS 32
FIGURE 3 NEUROMODULATION MARKET SHARE ANALYSIS, BY REVENUE, 2011 34
FIGURE 4 KEY GROWTH STRATEGIES, 2010 – 2012 107